Anima Biotech signs $1.05bn discovery and development deal with Lilly

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/HeitiPaves)
(Image: Getty/HeitiPaves)

Related tags: Drug discovery, Lilly, Technology, Big data

Anima Biotech is eligible to receive up to $1.05bn as part of a multi-year drug discovery and development agreement with Lilly.

Under the exclusive agreement with Eli Lilly and Company, Anima Biotech will use its technology platform for the discovery and development of translation inhibitors for several undisclosed target proteins.

According to the company, Anima’s Translation Control Platform is “strategically structured for collaborations with multiple pharma partners.”​ The technology combines “new biology with proprietary image analysis and high-performance big data software,”​ and is protected by five patents.

Lilly will be responsible for clinical development and any potential product commercialization.

Anima will receive $30m in upfront payments and $14m in research funding and is eligible to receive up to $1.05bn if it achieves all future development and commercial milestones.

Additionally, Anima is entitled to low- to mid-single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

Anima Biotech has not responded to a request for comment.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars